Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.

Abstract: Disclosed herein are granulocyte-macrophage colony-stimulating factor (GM-CSF) peptides and compositions comprising GM-CSF peptides. These molecules may be useful for the treatment of neurological diseases or conditions.

Abstract: Peptide conjugates comprising a peptide selected from a peptide that modulates the PYY receptor, a peptide that modulates both the GLP-1 receptor and the GCG receptor, a peptide that modulates both the GLP-1 receptor and the GIP receptor, and a peptide that modulates the GLP-1 receptor; and a staple attached to the peptide at a first amino acid and a second amino acid are disclosed herein. Also provided are peptide conjugates comprising prolactin-releasing peptide. The peptide conjugates may be used for treating conditions such as obesity. Further provided are stapled prolactin-releasing peptide.

Abstract: Peptide conjugates comprising a peptide that modulates the GLP-2 receptor are provided. The peptide conjugates may be used for treating conditions responsive to modulation of the GLP-2 receptor. Further provided are stapled GLP-2 peptide conjugates.

Abstract: The invention provides tumor targeting, immune checkpoint-blocking bispecific molecules. The bispecific molecules contain an anti-PD-L1 antibody or antigen-binding fragment, and a peptide agent that specifically binds to a surface antigen or cellular marker of a solid tumor. Also provided in the invention are methods of using such specific molecules in various therapeutic applications.

Abstract: The present invention provides myosin derived peptides, variants and derivative compounds that are anti-coagulant. Also provided in the invention are antibodies that specifically target the peptides or epitopes presented thereon. Further provided in the invention are methods directed to using the anti-coagulant compounds described herein in therapeutic applications, e.g., inhibiting myosin-supported prothrombin activation to reduce the risk of acute trauma coagulopathy in post-trauma patients or inhibiting cardiac myosin-supported prothrombin activation to reduce the risk of coronary thrombosis.

Abstract: Disclosed herein are compounds, compositions, and methods of their use for the treatment of diabetes.

Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.

Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.

Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.

Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. One or more half-life extending moieties may be attached to a therapeutic agent, thereby extending the half life of the therapeutic agent. The modified therapeutic agents (mTAs) comprising one or more half-life extending moieties attached to a therapeutic agent may be used to treat a disease or condition in a subject in need thereof.

Abstract: Disclosed herein are compounds, compositions, and methods of their use for the treatment of diabetes.

Abstract: Disclosed herein are compounds, compositions, and methods of their use for the treatment of diabetes.

Abstract: A quench protection apparatus includes a number N of superconducting coils and a heater matrix. The number N of superconducting coils are electrically coupled in series. The heater matrix module includes the number N of heater units. The number N of heater units is electrically coupled in parallel with the number N of superconducting coils respectively. A number M of the heater units each includes at least the number N of heaters. Each superconducting coil is thermally coupled with at least one heater of each of the number M of the heater units. The number of N-M of the heater units each includes at least one heater. Each of the number M of superconducting coils correspondingly coupled with the number M of the heater units is thermally coupled with at least one heater of each of the number N-M of the heater units. A superconducting magnet system protected by above quench protection apparatus is also provided.

Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. One or more half-life extending moieties may be attached to a therapeutic agent, thereby extending the half life of the therapeutic agent. The modified therapeutic agents (mTAs) comprising one or more half-life extending moieties attached to a therapeutic agent may be used to treat a disease or condition in a subject in need thereof.

Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. One or more half-life extending moieties may be attached to a therapeutic agent, thereby extending the half life of the therapeutic agent. The modified therapeutic agents (mTAs) comprising one or more half-life extending moieties attached to a therapeutic agent may be used to treat a disease or condition in a subject in need thereof.

Abstract: Described herein, inter alia, are compositions of ErbB modulators and methods of using the same.

Abstract: A system and method for magnetic field distortion compensation includes a cryostat for a magnetic resonance imaging (MRI) system. The cryostat includes a vacuum casing having a vacuum therein. A cryogen vessel is disposed within the casing, the vessel having a coolant therein. A thermal shield is disposed between the vacuum casing and the cryogen vessel. An eddy current compensation assembly is disposed within the casing. The eddy current compensation assembly includes a plurality of electrically conductive loops formed on one of the vacuum casing, the cryogen vessel, and the thermal shield and constructed to mitigate vibration-induced eddy currents in the MRI system.